Heron Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Heron Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Heron Therapeutics Inc Strategy Report
- Understand Heron Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Heron Therapeutics Inc (Heron) is engaged in the development of novel, patient-focused therapeutic products using its proprietary Biochronomer polymer-based drug delivery technology to address major unmet medical needs. It designs, develops and commercializes products for patients suffering from cancer and pain.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Heron’s research and development (R&D) focuses on developing novel, best-in-class treatments to address some of the major unmet patient needs. It develops patient-focused solutions by applying its innovative science and technologies. In FY2022, the company reported R&D expenses of US$107.5 million. This decrease in R&D expenses was primarily due to decreases in personnel and decrease in costs related to APONVIE, CINVANTI and HTX-034. The company has employed 63 people in R&D initiatives. The company had a total of 33 issued patents in the US and an additional 111 issued (or registered) foreign patents. The patents on the bioerodible technologies expire in March 2026. CINVANTI is has 9 patents issued in the U.S. and three patents that is issued (or registered) in foreign countries including Korea and Japan; SUSTOL also covered by 6 patents issued in the U.S. and 18 patents issued (or registered) in foreign countries including Spain, Sweden, Switzerland, Taiwan, France, Germany, Hong Kong, Ireland, Italy, Japan and the United Kingdom; ZYNRELEF has 15 patents issued in the U.S. and 89 patents issued (or registered) in foreign countries including Czech Republic, Denmark, Mexico, Monaco, Netherlands, Norway, Poland, Portugal, and others.
Product Categories
Overview
Cinvanti (aprepitant) is an IV formulation of aprepitant, an neurokinin-1 (NK1) receptor antagonist. It is approved by the FDA for the prevention of acute and delayed nausea and vomiting (CINV) associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC); and nausea and vomiting associated with moderately emetogenic cancer chemotherapy (MEC). - Cinvanti is distributed in the US through a few specialty distributors and full-line wholesalers who subsequently resell Cinvanti to healthcare providers and hospitals.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Sustol (granisetron) extended-release injection for the prevention of chemotherapy-induced nausea and vomiting (CINV). It is indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. - Sustol is an extended-release 5-hydroxytryptamine type 3 (5-HT3) receptor MEC and AC combination chemotherapy regimens. It is approved by the US FDA. - Sustol is distributed in the US through a few specialty distributors who subsequently resell it to healthcare providers.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Zynrelef (HTX-011) a non-opioid, sustained-release product, used as a combination of local anesthetic bupivacaine and anti-inflammatory Meloxicam.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer